Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on findings from the first-in-human trial (NCT06004245) of RO7589831, a WRN inhibitor, in patients with advanced microsatellite instability (MSI) and/or mismatch repair-deficient (dMMR) solid tumors. RO7589831 demonstrated a favorable safety profile and early signals of efficacy, including partial responses and metabolic activity in post-immunotherapy settings. Durable disease control and ctDNA responses support its potential as a targeted approach for patients with limited options following immune checkpoint inhibitor failure. Dose optimization is ongoing. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
